TABLE 1.
Overview of biologic therapies approved in the United States for patients with moderate-to-severe plaque psoriasis, by route of administration
| ROUTE OF ADMINISTRATION | DRUG | DOSAGE | INDICATION | MECHANISM OF ACTION |
|---|---|---|---|---|
| SC injection administered by an HCP | Tildrakizumab4 | 100mg at Weeks 0 and 4, then every 12 weeks | Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy | IL-23 p19 inhibitor |
| IV infusion administered by an HCP | Infliximab5 | 5mg/kg at Weeks 0, 2, and 6, then every 8 weeks | Adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate | TNF-α inhibitor |
| SC injection that may be self-administered by the patient or an HCPa | Etanercept10 | Adults: 50mg twice weekly for 3 months, then 50mg once weekly; pediatric patients: 0.8mg/kg weekly, maximum of 50mg/week | Plaque psoriasis in patients ≥4 years of age | TNF-α inhibitor |
| Adalimumab9 | 80mg initial dose, then 40mg every other week starting 1 week after initial dose | Adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate | TNF-α inhibitor | |
| Certolizumab14 | 400mg (two 200mg SC injections) every other week; in patients with body weight ≤90 kg, 400mg (two 200mg SC injections) initially and at Weeks 2 and 4, then 200mg every other week may be considered | Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy | TNF-α inhibitor | |
| Ustekinumab13 | Adult/pediatric patients >100kg: 90mg initially and at Week 4, then 90mg every 12 weeks; adults ≤100kg/pediatric patients 60–100kg: 45mg initially and Week 4, then 45mg every 12 weeks; pediatric patients <60kg: 0.75mg/kg initially and at Week 4, then every 12 weeks | Patients ≥6 years of age with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy | IL-12/23 p40 inhibitor | |
| Secukinumab8 | Adults: 300mg at Weeks 0, 1, 2, 3, and 4, then 300mg every 4 weeks (150mg doses may be acceptable for some patients); pediatric patients: dosage based on body weight (<50kg, 75mg; ≥50kg, 150mg) at Weeks 0, 1, 2, 3, and 4, then every 4 weeks | Moderate-to-severe plaque psoriasis in patients ≥6 years of age who are candidates for systemic therapy or phototherapy | IL-17A inhibitor | |
| Ixekizumab7 | Adults: 160mg (two 80mg injections) at Week 0; 80mg at Weeks 2, 4, 6, 8, 10, and 12; then 80mg every 4 weeks; pediatric patients (by body weight): >50kg: 160mg (two 80mg injections) at Week 0, then 80 mg every 4 weeks; 25–50kg: 80mg at Week 0, then 40mg every 4 weeks; <25kg: 40mg at Week 0, then 20mg every 4 weeks | Patients ≥6 years of age with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy | IL-17A inhibitor | |
| Brodalumab6 | 210mg at Weeks 0, 1, and 2, then 210mg every 2 weeks | Moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies | IL-17RA inhibitor | |
| SC injection that may be self-administered by the patient or an HCPa | Guselkumab12 | 100mg at Week 0 and Week 4, then every 8 weeks | Adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy | IL-23 p19 inhibitor |
| Risankizumab11 | 150mg at Week 0 and Week 4, then every 12 weeks | Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy | IL-23 p19 inhibitor |
aPatients should not self-administer until they receive proper training. HCP: healthcare professional; IL: interleukin; IV: intravenous; SC: subcutaneous; TNF: tumor necrosis factor